Enhancing the immune response against acute myeloid leukemia using specialized antibodies
Promoting immunity against acute myeloid leukemia through Fc effector-optimized antibody inhibitory of MICA/B shedding
['FUNDING_R37'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-10992151
This study is looking at a new way to help your immune system fight acute myeloid leukemia (AML) by using special antibodies that keep important signals on leukemia cells from disappearing, making it easier for your body's immune cells to find and destroy the cancer.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10992151 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the immune system's ability to fight acute myeloid leukemia (AML) by using specially designed antibodies that prevent the shedding of important surface proteins on leukemia cells. These proteins, known as MICA and MICB, act as signals to alert immune cells, such as natural killer (NK) cells and macrophages, to attack the cancer cells. The study aims to develop a new version of an antibody that enhances the recognition and destruction of AML cells by these immune cells, potentially leading to better treatment outcomes for patients. By blocking the mechanisms that allow leukemia cells to evade the immune response, this research seeks to create a more effective therapeutic approach for AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking innovative treatment options.
Not a fit: Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, improving their chances of recovery.
How similar studies have performed: Previous research has shown promising results with similar antibody-based approaches in enhancing immune responses against cancer, indicating potential for success in this novel application.
Where this research is happening
NEW YORK, UNITED STATES
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FERRARI DE ANDRADE, LUCAS — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Study coordinator: FERRARI DE ANDRADE, LUCAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.